This HTML5 document contains 45 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
schemahttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
rdfshttp://www.w3.org/2000/01/rdf-schema#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q63405353
rdf:type
wikibase:Item
schema:description
клінічне випробування կլինիկական փորձարկում ensayu clínicu klinisch onderzoek clinical trial
rdfs:label
Proof-of-Concept Study of a Selective p38 MAPK Alpha Inhibitor, Neflamapimod, in Subjects With Mild Alzheimer's Disease
skos:prefLabel
Proof-of-Concept Study of a Selective p38 MAPK Alpha Inhibitor, Neflamapimod, in Subjects With Mild Alzheimer's Disease
schema:name
Proof-of-Concept Study of a Selective p38 MAPK Alpha Inhibitor, Neflamapimod, in Subjects With Mild Alzheimer's Disease
p:P1476
wds:Q63405353-1802AA58-0773-40D4-9B01-7D4B117A99D1
wdt:P1476
A Double-Blind, Placebo-Controlled Proof-of-Concept Study of a Selective p38 MAP Kinase Alpha Inhibitor, Neflamapimod, Administered for 24 Weeks in Subjects With Mild Alzheimer's Disease
p:P582
wds:Q63405353-65749C4B-4F71-491D-A4EF-8A9F6946806C
wdt:P582
2019-06-30T00:00:00Z
p:P31
wds:Q63405353-BB60A166-8C58-4A04-918D-7DC99C54F151
wdt:P31
wd:Q30612
p:P580
wds:Q63405353-18DBB288-A54F-4CF5-A3EC-2CCBF357388E
wdt:P580
2017-12-29T00:00:00Z
p:P17
wds:Q63405353-497F78B6-6DE7-4D09-9E76-D001270D4DF3 wds:Q63405353-84F2D339-C5BA-4AAF-9423-A310E405DBC1 wds:Q63405353-89622F9A-64EC-4226-AD46-630271F9E49A wds:Q63405353-8E890DA4-32FE-4EF7-BC6E-864416894B9B
wdt:P17
wd:Q55 wd:Q30 wd:Q35 wd:Q145
p:P6153
wds:Q63405353-6F1F2182-86FE-4016-A291-0A0AAFC4AA3F wds:Q63405353-467FBDDB-BFFD-4ED4-94E5-7ADA7465F171 wds:Q63405353-5F839D43-8B94-49FB-B27E-1BB5E0D14CDD
wdt:P6153
wd:Q2205932 wd:Q30270351 wd:Q30282378
p:P1813
wds:Q63405353-A562DBC3-7D3C-4C0C-BBDE-F8BC3BBEF622
wdt:P1813
REVERSE-SD
p:P2899
wds:Q63405353-E738F001-C670-4080-9876-119F6D87CA27
wdt:P2899
55
p:P1132
wds:Q63405353-B86EF883-E638-4453-B439-E0381BF7F9A5
wdt:P1132
161
p:P4135
wds:Q63405353-D1B8AA54-6B97-4027-82FA-231554C853CE
wdt:P4135
85
p:P8363
wds:Q63405353-7F9B6785-64C2-4C36-8326-0AB6CD50C401
wdt:P8363
wd:Q78089383
p:P3098
wds:Q63405353-D9AF1830-371A-43C5-AF2E-9D97B793F19F
wdt:P3098
NCT03402659
p:P6099
wds:Q63405353-C171D606-1463-41B6-8B44-942EECFDCB69
wdt:P6099
wd:Q42824440